Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,147
archived clinical trials in
Asthma

Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma
Status: Archived
Novartis Investigative Site
mi
from
Mt. Pleasant, SC
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Novartis Investigative Site
mi
from
Mt. Pleasant, SC
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma
Status: Archived
Novartis Investigator Site
mi
from
Kingsport, TN
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Novartis Investigator Site
mi
from
Kingsport, TN
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma
Status: Archived
Novartis Investigator Site
mi
from
Dallas, TX
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Novartis Investigator Site
mi
from
Dallas, TX
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma
Status: Archived
Novartis Investigative site
mi
from
Dallas, TX
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Novartis Investigative site
mi
from
Dallas, TX
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma
Status: Archived
Novartis Investigative Site
mi
from
South Burlington, VT
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Novartis Investigative Site
mi
from
South Burlington, VT
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma
Status: Archived
Novartis Investigative Site
mi
from
Abingdon, VA
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Novartis Investigative Site
mi
from
Abingdon, VA
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma
Status: Archived
Novartis Investigator Site
mi
from
Kirkland, WA
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Novartis Investigator Site
mi
from
Kirkland, WA
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma
Status: Archived
Novartis Investigator Site
mi
from
Milwaukee, WI
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Novartis Investigator Site
mi
from
Milwaukee, WI
Randomized Controlled Trial of Silymarin in Asthma
Antioxidant Enzyme Induction as a New Approach to Therapy in Patients With Asthma
Status: Archived
Vanderbilt University Medical Center
mi
from
Nashville, TN
Randomized Controlled Trial of Silymarin in Asthma
Antioxidant Enzyme Induction as a New Approach to Therapy in Patients With Asthma
Status: Archived
Updated: 1/1/1970
Vanderbilt University Medical Center
mi
from
Nashville, TN
The Community United to Challenge Asthma
A Community-Academic Partnership to Improve Asthma Management in Latino Children
Status: Archived
Rush University Medical Center
mi
from
Chicago, IL
The Community United to Challenge Asthma
A Community-Academic Partnership to Improve Asthma Management in Latino Children
Status: Archived
Updated: 1/1/1970
Rush University Medical Center
mi
from
Chicago, IL
The Community United to Challenge Asthma
A Family Intervention for Pediatric Asthma Self-Management in Puerto Ricans
Status: Archived
Rush University Medical Center
mi
from
Chicago, IL
The Community United to Challenge Asthma
A Family Intervention for Pediatric Asthma Self-Management in Puerto Ricans
Status: Archived
Updated: 1/1/1970
Rush University Medical Center
mi
from
Chicago, IL
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01043 Boehringer Ingelheim Investigational Site
mi
from
Tucson, AZ
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01043 Boehringer Ingelheim Investigational Site
mi
from
Tucson, AZ
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01009 Boehringer Ingelheim Investigational Site
mi
from
Cypress, CA
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01009 Boehringer Ingelheim Investigational Site
mi
from
Cypress, CA
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01040 Boehringer Ingelheim Investigational Site
mi
from
Palmdale, CA
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01040 Boehringer Ingelheim Investigational Site
mi
from
Palmdale, CA
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01024 Boehringer Ingelheim Investigational Site
mi
from
San Jose, CA
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01024 Boehringer Ingelheim Investigational Site
mi
from
San Jose, CA
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01003 Boehringer Ingelheim Investigational Site
mi
from
Stockton, CA
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01003 Boehringer Ingelheim Investigational Site
mi
from
Stockton, CA
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01015 Boehringer Ingelheim Investigational Site
mi
from
Colorado Springs, CO
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01015 Boehringer Ingelheim Investigational Site
mi
from
Colorado Springs, CO
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Denver, CO
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Denver, CO
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01016 Boehringer Ingelheim Investigational Site
mi
from
Lakewood, CO
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01016 Boehringer Ingelheim Investigational Site
mi
from
Lakewood, CO
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1222.29.11012 Boehringer Ingelheim Investigational Site
mi
from
Wheat Ridge, CO
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1222.29.11012 Boehringer Ingelheim Investigational Site
mi
from
Wheat Ridge, CO
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01045 Boehringer Ingelheim Investigational Site
mi
from
Deland, FL
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01045 Boehringer Ingelheim Investigational Site
mi
from
Deland, FL
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01036 Boehringer Ingelheim Investigational Site
mi
from
Normal, IL
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01036 Boehringer Ingelheim Investigational Site
mi
from
Normal, IL
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01025 Boehringer Ingelheim Investigational Site
mi
from
South Bend, IN
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01025 Boehringer Ingelheim Investigational Site
mi
from
South Bend, IN
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01005 Boehringer Ingelheim Investigational Site
mi
from
Iowa City, IA
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01005 Boehringer Ingelheim Investigational Site
mi
from
Iowa City, IA
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Baltimore, MD
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Baltimore, MD
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1222.29.11004 Boehringer Ingelheim Investigational Site
mi
from
North Dartmouth, MA
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1222.29.11004 Boehringer Ingelheim Investigational Site
mi
from
North Dartmouth, MA
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01027 Boehringer Ingelheim Investigational Site
mi
from
Novi, MI
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01027 Boehringer Ingelheim Investigational Site
mi
from
Novi, MI
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1199.15.10103 Boehringer Ingelheim Investigational Site
mi
from
Minneapolis, MN
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1199.15.10103 Boehringer Ingelheim Investigational Site
mi
from
Minneapolis, MN
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1222.29.11011 Boehringer Ingelheim Investigational Site
mi
from
St Louis, MO
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1222.29.11011 Boehringer Ingelheim Investigational Site
mi
from
St Louis, MO
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01022 Boehringer Ingelheim Investigational Site
mi
from
Bozeman, MT
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01022 Boehringer Ingelheim Investigational Site
mi
from
Bozeman, MT
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01008 Boehringer Ingelheim Investigational Site
mi
from
Bellevue, NE
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01008 Boehringer Ingelheim Investigational Site
mi
from
Bellevue, NE
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01044 Boehringer Ingelheim Investigational Site
mi
from
Bayside, NY
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01044 Boehringer Ingelheim Investigational Site
mi
from
Bayside, NY
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1222.29.11003 Boehringer Ingelheim Investigational Site
mi
from
Raleigh, NC
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1222.29.11003 Boehringer Ingelheim Investigational Site
mi
from
Raleigh, NC
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Cincinnati, OH
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Cincinnati, OH
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Oklahoma City, OK
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Oklahoma City, OK
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01031 Boehringer Ingelheim Investigational Site
mi
from
Easley, SC
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01031 Boehringer Ingelheim Investigational Site
mi
from
Easley, SC
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01039 Boehringer Ingelheim Investigational Site
mi
from
Fort Mill, SC
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01039 Boehringer Ingelheim Investigational Site
mi
from
Fort Mill, SC
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Greenville, SC
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Greenville, SC
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Dallas, TX
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Dallas, TX
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01012 Boehringer Ingelheim Investigational Site
mi
from
El Paso, TX
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01012 Boehringer Ingelheim Investigational Site
mi
from
El Paso, TX
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01048 Boehringer Ingelheim Investigational Site
mi
from
Killeen, TX
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01048 Boehringer Ingelheim Investigational Site
mi
from
Killeen, TX
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1268.17.01028 Boehringer Ingelheim Investigational Site
mi
from
New Braunfels, TX
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1268.17.01028 Boehringer Ingelheim Investigational Site
mi
from
New Braunfels, TX
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
1218.64.10010 Boehringer Ingelheim Investigational Site
mi
from
Tacoma, WA
BI 671800 ED in Steroid-naive Asthmatic Patients
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Status: Archived
Updated: 1/1/1970
1218.64.10010 Boehringer Ingelheim Investigational Site
mi
from
Tacoma, WA
Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM
Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM
Status: Archived
Arizona State University
mi
from
Phoenix, AZ
Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM
Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM
Status: Archived
Updated: 1/1/1970
Arizona State University
mi
from
Phoenix, AZ